Systems and methods for the detection of infectious diseases

Abstract

The present invention relates to method of detecting and characterizing one or more Borrelia species causing Lyme Disease or tick-borne relapsing fever within a sample from a subject, the method comprising: a) subjecting DNA and/or RNA from the sample to a PCR amplification reaction using primer pairs targeting at least one region of Borrelia 16S rRNA and at least one region of flaB, ospA, ospB, ospC, glpQ, 16S-23S intergenic spacer (IGS1), 5S-23S intergenic spacer (IGS2), bbk32, dbpA, dbpB, and/or p66; and b) analyzing amplification products resulting from the PCR amplification reaction to detect the one or more Borrelia species.

We claim: 
     
         1 . A kit for detection of at least one  Borrelia  species causing Lyme Disease or tick-borne relapsing fever (TBRF), the kit comprising:
 primer pairs targeting at least one region of  Borrelia  16S rRNA and at least one region of flaB, ospA, ospB, ospC, glpQ, 16S-23S intergenic spacer (IGS1), 5S-23S intergenic spacer (IGS2), bbk32, dbpA, dbpB, and/or p66.   
     
     
         2 . The kit of  claim 1 , wherein primer pairs targeting the least one region of  Borrelia  16S rRNA comprises sequences selected from the group consisting of: SEQ ID NOS: 1-10. 
     
     
         3 . The kit of  claim 2 , wherein the primer pairs targeting at least one region of flaB, ospA, ospB, ospC, glpQ, 16S-23S intergenic spacer (IGS), 5S-23S intergenic spacer (IGS2), bbk32, dbpA, dbpB, and/or p66 contain sequences selected from the group consisting of SEQ ID NOS: 11-48, SEQ ID NOS: 60-77, SEQ ID NOS: 97-100, and SEQ ID NOS: 219-293. 
     
     
         4 . The kit of  claim 3 , further comprises primer pairs containing sequences selected from the group consisting of SEQ ID NOS: 49-59, SEQ ID NOS: 78-96, SEQ ID NOS: 105-108, and SEQ ID NOS: 294-314. 
     
     
         5 . The kit of  claim 4 , further comprising a nucleotide polymerase, buffer, diluent, and/or excipien one or more primers comprising a sequence selected from SEQ ID NOS: 109 and 110 for amplifying human GAPDH as an internal control. 
     
     
         6 . The kit of  claim 1 , wherein the primer pairs are labeled 
     
     
         7 . The kit of  claim 6 , wherein the labeled primer pairs comprise a universal tail sequence. 
     
     
         8 . The kit of  claim 6 , wherein the labeled primer pairs comprise chain termination bases is labeled with a fluorescent label of a different wavelength that allows the sequencing to be performed in a single reaction. 
     
     
         9 . A kit for detecting one or more  Borrelia  species causing Lyme Disease or tick-borne relapsing fever (TBRF) within a sample from a subject, the kit comprising:
 a) primers targeting:
 at least one region of  Borrelia  16S rRNA; 
 at least one region of a 16S-23S intergenic spacer (IGS1); 
 at least one region of a 5S-23S intergenic spacer (IGS2); 
 at least one region of a flagella subunit B (flaB) gene; 
 at least one region of a bbk32 gene; 
 at least one region of a dbpA gene; 
 at least one region of a dbpB gene; 
 at least one region of an ospA gene 
 at least one region of an ospB gene; 
 at least one region of an ospC gene; 
 at least one region of a p66 porin gene; and 
 at least one region of a glpQ gene. 
   
     
     
         10 . The kit of  claim 9 , wherein the at least one region of  Borrelia  16S rRNA contain sequences selected from the group consisting of: SEQ ID NOS: 1-10. 
     
     
         11 . The kit of  claim 10 , wherein:
 the at least one region of the 16S-23 S intergenic spacer (IGS1) contains sequences selected from the group consisting of SEQ ID NOS: 17-20 and 219-232;   the at least one region of the 5S-23S intergenic spacer (IGS2) contains sequences selected from the group consisting of SEQ ID NOS: 11-16;   the at least one region of the flagella subunit B (flaB) gene contains sequences selected from the group consisting of SEQ ID NOS: 21-29;   the at least one region of the bbk32 gene contains sequences selected from the group consisting of SEQ ID NOS: 41-44;   the at least one region of the dbpA gene contains sequences selected from the group consisting of SEQ ID NOS: 45-46 and 233-239;   the at least one region of the dbpB gene contains sequences selected from the group consisting of SEQ ID NOS: 47-48 and 240-248;   the at least one region of the ospA gene contains sequences selected from the group consisting of SEQ ID NOS: 274-293;   the at least one region of the ospB gene contains sequences selected from the group consisting of SEQ ID NOS: 60-63 and 249-261;   the at least one region of the ospC gene contains sequences selected from the group consisting of SEQ ID NOS: 64-69 and 262-263;   the at least one region of the p66 porin gene contains sequences selected from the group consisting of SEQ ID NOS: 70-75 and 264-273; and   the at least one region of the glpQ gene contains sequences selected from the group consisting of SEQ ID NOS: 30-40.   
     
     
         12 . The method of  claim 9 , wherein the amplification products are analyzed by size determination with agarose gel electrophoresis. 
     
     
         13 . The kit of  claim 9 , wherein the primer pairs comprise a universal tail sequence. 
     
     
         14 . The kit of  claim 9 , wherein the one or more  Borrelia  species are selected from the group consisting of:  Borrelia afzelii, Borrelia americana, Borrelia andersonii, Borrelia anserina, Borrelia baltazardii, Borrelia bavariensis, Borrelia bissettii, Borrelia brasiliensis, Borrelia burgdorferi, Borrelia californiensis, Borrelia carolinensis, Borrelia caucasica, Borrelia coriaceae, Borrelia crocidurae, Borrelia dugesii, Borrelia duttonii, Borrelia garinii, Borrelia graingeri, Borrelia harveyi, Borrelia hermsii, Borrelia hispanica, Borrelia japonica, Borrelia kurtenbachii, Borrelia latyschewii, Borrelia lonestari, Borrelia lusitaniae, Borrelia mayonii, Borrelia mazzottii, Borrelia merionesi, Borrelia microti, Borrelia miyamotoi, Borrelia parkeri, Borrelia persica, Borrelia queenslandica, Borrelia recurrentis, Borrelia sinica, Borrelia spielmanii, Borrelia tanukii, Borrelia theileri, Borrelia tillae, Borrelia turcica, Borrelia turdi, Borrelia turicatae, Borrelia valaisiana, Borrelia venezuelensis, Borrelia vincentii , and  Candidatus Borrelia texasensis.    
     
     
         15 . The kit of  claim 9 , wherein the one or more  Borrelia  species are selected from the group consisting of:  Borrelia burgdorferi, Borrelia garinii, Borrelia mayonii , and  Borrelia afzelii.    
     
     
         16 . The kit of  claim 9 , further comprising detecting in the sample a  Babesia  species, an  Ehrlichia  species, a  Bartonella  species,  Francisella tularensis, Yersinia pestis, Staphylococcus aureus, Anaplasma phagocytophilum , Enterovirus, Powassan and deer tick virus,  Rickettsia  species, and/or Influenza by subjecting the DNA and/or RNA from the sample to a second PCR amplification reaction using primer pairs containing sequences selected from the group consisting of:
 SEQ ID NOS: 49-55 for detection of  Anaplasma phagocytophilum;      SEQ ID NOS: 56-59 for detection of an  Ehrlichia  species;   SEQ ID NOS: 78-86 for detection of Enterovirus;   SEQ ID NOS: 87-88 for detection of  Staphylococcus aureus;      SEQ ID NOS: 89-90 for detection of Influenza;   SEQ ID NOS: 91-94 for detection of  Yersinia pestis;      SEQ ID NOS: 95-96 for detection of  Francisella tularensis;      SEQ ID NOS: 105-106 for detection of a  Bartonella  species;   SEQ ID NOS: 107-108 for detection of a  Babesia  species;   SEQ ID NOS: 294-310 for detection of a  Rickettsia  species; and   SEQ ID NOS: 311-314 for detection of a Powassan and deer tick virus.   
     
     
         17 . The kit of  claim 9 , further comprises a nucleotide polymerase, buffer, diluent, and/or excipient; one or more primers comprising a sequence selected from SEQ ID NOS: 109 and 110 for amplifying human GAPDH as an internal control; and the primer pairs are labeled 
     
     
         18 . A method of detecting one or more  Borrelia  species causing Lyme Disease or tick-borne relapsing fever (TBRF) within a sample from a subject, the method comprising:
 a) subjecting DNA and/or RNA from the sample to a multiplex PCR amplification reaction with primers targeting:
 at least one region of  Borrelia  16S rRNA; 
 at least one region of a 16S-23S intergenic spacer (IGS1); 
 at least one region of a 5S-23S intergenic spacer (IGS2); 
 at least one region of a flagella subunit B (flaB) gene; 
 at least one region of a bbk32 gene; 
 at least one region of a dbpA gene; 
 at least one region of a dbpB gene; 
 at least one region of an ospA gene 
 at least one region of an ospB gene; 
 at least one region of an ospC gene; 
 at least one region of a p66 porin gene; and 
 at least one region of a glpQ gene; and 
   b) analyzing amplification products resulting from the PCR amplification reaction to detect the one or more  Borrelia  species.   
     
     
         19 . The method of  claim 18 , wherein the amplification products are analyzed to determine the sequence of each amplification product. 
     
     
         20 . The method of  claim 18 , wherein the sequence of each amplification product is mapped to a reference library of known  Borrelia  sequences to detect the one or more  Borrelia  species and to identify  Borrelia  species that cause Lyme Disease and  Borrelia  species that do not cause Lyme Disease.